Erlotinib plus chemotherapy was evaluated as first-line therapy in patients with advanced/metastatic NSCLC with or without common EGFR mutation in the phase 2 trial CALGB 30406 [56]. Here, EGFR is linked to non-small cell lung carcinoma.